Get to Know the Assets
Behind the Smart Portfolios

Get to Know the Assets Behind the Smart Portfolios

Closing price of 30 April 2025: $192.89

Performance: April: 5.54% | 2025: 14.99% | Past 12 months: 49.23% | Past 24 months: 215.23%

DoorDash, Inc. is an online food ordering and delivery company. It develops technology to connect customers with merchants through an on-demand food delivery application. The company has offered to buy UK-based Deliveroo for $3.6 billion, marking a renewed attempt by DoorDash to expand into more overseas markets by buying smaller food delivery providers.

San Francisco-based DoorDash owns two-thirds of the restaurant delivery market in the US, and is present in more than 30 countries, including continental Europe, Japan and Australia. eToro's GigEconomy Smart Portfolio allocates capital to companies that benefit from an innovative workforce, from partnering with drivers, or helping individuals offer their apartments as “vacation homes.”

Cancer-Med

Closing price of 30 April 2025: $47.23

Performance: April: 10.87% | 2025: 54.60% | Past 12 months: 162.39% | Past 24 months: 109.35%

Guardant Health, Inc. operates as a biotechnology company, providing sequencing and cell diagnostics services for cancer patients. In April, Guardant announced a strategic collaboration with Pfizer to support the development and commercialisation of Pfizer’s oncology portfolio using the Guardant Infinity smart liquid biopsy. The deal makes Guardant products a preferred tool across Pfizer's global oncology trials.

Guardant’s liquid biopsy tests analyse circulating tumour DNA from a simple blood draw. This approach eliminates the need for invasive tissue biopsies, which can slow down trial enrolment and limit how frequently tumour changes can be monitored. eToro's Cancer-Med Smart Portfolio focuses on leading biotechnology companies that manufacture drugs used to treat the various types of cancer.

Fin-Tech

Closing price of 30 April 2025: GBp 978.50

Performance: April: 3.54% | 2025: -8.21% | Past 12 months: 26.01% | Past 24 months: 77.91%

Wise PLC is a financial technology company offering a platform to make international multi-currency money transfers. It offers digital money accounts and transfers to global clients in over 40 currencies. The UK-based company announced for the second half of 2025 a new full stack hub in Hyderabad, India, with plans to hire hundreds of employees in the coming years. The new Wise hub teams will build new features localised to customer's needs across the region.

Wise is a fintech company that offers international money transfers more easily and cheaply than traditional banks. eToro's Fin-Tech Smart Portfolio invests in several spheres of the FinTech revolution that transform the financial services of our daily lives, including Paytech companies, InsurTech, LendingTech, RegTech, AccountingTech, WealthTech and more.

EmergingNations

Closing price of 30 April 2025: $205.06

Performance: April: 3.82% | 2025: -6.74% | Past 12 months: 18.48% | Past 24 months: 115.97%

Fabrinet is a Thailand-based company specialising in advanced optical packaging and precision manufacturing services. It primarily serves original equipment manufacturers (OEMs) in the optical communications, automotive, industrial, and medical device sectors. Fabrinet has partnered with Israel's Innoviz Technologies to manufacture Innoviz’s LiDAR sensors, crucial for autonomous vehicles, and will support a scalable production of Innoviz’s LiDAR units.

Fabrinet's expertise in complex, high-precision assemblies and outsourced manufacturing exemplifies the successful realisation of advanced technological potential in emerging countries. eToro's EmergingNations Smart Portfolio comprises companies from various sectors that are based in Emerging Markets, characterised by growing demographics, high potential for expansion, rising middle classes and increasing levels of international trade and investments.

CRISPR-Tech

Closing price of 30 April 2025: $14.76

Performance: April: 39.25% | 2025: -16.42% | Past 12 months: 234.69% | Past 24 months: -23.96%

uniQure N.V. is a gene therapy company. It develops a modular platform to bring new disease- modifying therapies to patients with severe genetic diseases, as well as offering ongoing clinical programs in hemophilia B. It was announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to AMT-130 for the treatment of Huntington's desease, a rare, inherited neurodegenerative disorder for which there are currently no disease-modifying therapies available.

Amsterdam-based uniQure developed the first gene therapy with EU approval, and has achieved major milestones in the field of genomic medicine with a treatment approach for patients living with hemophilia and now those with Huntington's disease. eToro's CRISPR-Tech Smart Portfolio consists of stocks in the biotech sphere involved in the gene-editing field of research and development.

Any of these Assets and businesses were new to you?

DoorDash Inc.
Guardant Health Inc.
Wise PLC
Fabrinet
uniQure N.V.